RPRX
Royalty Pharma plc
Biotechnology · Healthcare · United States
65.93
close · 2026-10-29
value
51
cheaper than peers51
quality
69
stronger fundamentals69
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 11.35× | 80 |
| price to sales | 13.21× | 49 |
| EV to EBITDA | 23.34× | 41 |
| price to book | 4.30× | 40 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 19.7% | 87 |
| return on equity | 14.0% | 85 |
| revenue growth | 16.5% | 48 |
| debt to equity | 91.6% | 23 |
4 of 4 measures available
Facts
| market cap | $38B |
| free cash flow | -$1.20B |
| employees | 100 |
| first trade | 2020-06-16 |
| next earnings | 2026-11-04 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.78 | 1.45 | 2.53 | 0.10 |
| free cash flow | $2.49B | $2.77B | $2.99B | $2.14B |
| net income | $770.9M | $859.0M | $1.13B | $42.8M |
| revenue | $2.38B | $2.26B | $2.35B | $2.24B |
| unusual items | $24.0M | $188.5M | $315.7M | -$559.5M |